9th Joint ECTRIMS-ACTRIMS meeting – 11-13 October 2023
The following summarizes some of the highlights from Day 1 of ECTRIMS-ACTRIMS 2023.
Latest News
EYE TRACKING AS A BIOMARKER OF MS SEVERITY (NEUROSOUND PODCAST)
October 3, 2023Click here to listen to the podcast
A McGill University study has examined the potential usefulness of tracking eye movements as a biomarker of physical and cognitive dysfunction in patients with multiple sclerosis (de Villers-Sidani et al. Front Neurol 2023;14:1243594). Read More
CLINICAL CASES IN MS – WORSENING SYMPTOMS PRIOR TO OCRELIZUMAB INFUSION
September 27, 2023Click here to watch Dr. Virginia Devonshire discuss the case and the responses to the survey.
Thomas, 38, is a chemical engineer who initially presented in 2019 with optic neuritis followed two months later by a myelopathic episode. MRI was highly active with two gadolinium-enhancing T1 and multiple T2 lesions. EDSS was 2.5 (optic 1, sensory 2, bladder 2). Thomas had no relevant medical conditions other than obesity; his body weight was 120 kg (BMI 34 kg/m2) at presentation. Read More
Ofatumumab – update on long-term efficacy, safety
September 25, 2023SPECIAL REPORT
Long-term treatment with ofatumumab, a fully human anti-CD20 monoclonal antibody, is associated with a favourable safety profile and sustained efficacy, according to a newly-published analysis of the ALITHIOS long-term extension (Hauser et al. Mult Scler 2023; epublished September 11, 2023). The study is the most recent to support the earlier use of high-efficacy therapy in patients with multiple sclerosis. Read More